News & Events Year None202120202019201820172016201520142013201220112009 04/14/21 REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) 03/01/21 REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights 02/24/21 REGENXBIO to Participate in Upcoming Investor Conferences 02/22/21 REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights 02/16/21 REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD 02/08/21 REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021 02/05/21 REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
